$ADRX

ADARx Pharmaceuticals (ADRX) reported Q3 2026 revenue of $2.2M, up from $1.6M in 2025, with R&D and G&A expenses rising. Net loss widened to $28.1M. The company has $901M in cash and expects funds to last until 2030. ADARx advanced clinical trials for agazisiran and onvuzosiran, with key data expected in 2027. The company completed an IPO raising $513.2M and a private placement with AbbVie for $89.3M.

ADARx Pharmaceuticals, Inc. (ADRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates – Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations

UBS initiated coverage on Adarx Pharmaceuticals (ADRX) with a 'Buy' rating and a $35.00 price target, citing confidence in its RNA-targeting medicines. ADRX's current price is $17.63, with a GF Score of 8/100. Insider buying totals $87.7M in the last three months. The company has a market cap of $1.95B and focuses on siRNA therapeutics for various diseases.

JPMorgan initiates coverage of ADARx Pharmaceuticals with an Overweight rating and a $38 price target. The stock is currently trading at $17.63, down 1.89% over the past year. Other analysts, including UBS and TD Cowen, have also initiated coverage with Buy ratings.

Morgan Stanley initiated coverage on ADARx Pharmaceuticals (NASDAQ:ADRX) with an overweight rating and a $32.00 price target, suggesting 81% upside. The company has a market cap of $1.98 billion and a pipeline of liver-targeted treatments. UBS and TD Cowen also initiated coverage with Buy ratings and higher price targets. ADARx recently completed an IPO, raising $446.3 million.

TD Cowen initiated coverage on ADARx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating, citing its siRNA technology. The stock trades near its 52-week low at $17.63, with a market cap of $1.98 billion. The firm highlights CEO Zhen Li's contributions and projects $14 billion in 2040 sales. ADARx completed an IPO, raising $446.3 million, and has a collaboration with AbbVie valued at $8 billion.

Simeon George, through SR One Capital Management, disclosed a 9.3% stake in ADARx Pharmaceuticals (ADRX) post-IPO. The investment includes converted preferred shares and IPO purchases, with a 180-day lock-up period. SR One plans long-term growth and holds registration rights post-lock-up. ADRX completed its IPO on Sept. 28, 2026.

OrbiMed Advisors disclosed a 14.0% stake in ADARx Pharmaceuticals (ADRX) post-IPO, acquiring shares at $17 each. The investment firm stated its intent is for investment, not control, and may buy or sell shares in the future. OrbiMed and affiliated directors agreed to a 180-day lock-up on sales.

ADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.

Chimovits Erez purchased 61,516 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($1.05M total) on 2026-09-28.